home-slide-2
Focused on Patients The Anaptys Team works to transform patient health by delivering innovative immunology therapeutics. The Anaptys team works to transform patient health by delivering innovative immunology therapeutics.
Theresa, working in the Anaptys lab
home-slide-2
Anaptys Overview A clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases. We are a clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases.
Sarah and Ben in an Anaptys conference room
home-slide-2
The Anaptys Difference Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance. Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance.
home-slide-2
Transparency, Accountability, Humility Embracing our core values to guide our efforts discovering and developing medicines that transform patient lives. Embracing our core values to guide our efforts discovering and developing medicines that transform patient lives.
May and Annie, reviewing a recent Immunology publication
home-slide-2
Recent Webcast Anaptys provides overview of rosnilimab a PD-1 agonist, at virtual R&D event Anaptys provides overview of rosnilimab, a PD-1 agonist, at virtual R&D event Latest Events

Press Releases

March 11, 2024
  • Anaptys News

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2023 and provided a business update.

February 29, 2024
  • Anaptys Events

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga , president and chief executive officer, will participate in a panel discussion at TD

January 31, 2024
  • Anaptys Events

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim’s 6th Annual Biotechnology Conference.